In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Edgewise Therapeutics, with a price target of $42.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Edgewise Therapeutics’ promising developments in treating Becker muscular dystrophy (BMD). The company’s investigational drug, sevasemten, is highlighted as a potential first-in-class therapy aimed at preventing muscle damage in BMD patients, a condition with no approved treatments currently. The drug’s progress, showcased at the 2025 International Annual Congress of the World Muscle Society, underscores its potential to address the unmet needs of BMD, a less severe but still debilitating form of muscular dystrophy compared to Duchenne.
Pantginis emphasizes the importance of functional assessments like the North Star Ambulatory Assessment (NSAA) in evaluating the disease-modifying potential of therapies like sevasemten. These assessments provide critical insights into the progression of muscular dystrophies and the functional benefits of investigational treatments. The promising clinical results associated with sevasemten, particularly in improving functional outcomes, contribute to Pantginis’s optimistic outlook and the Buy rating for Edgewise Therapeutics.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EWTX in relation to earlier this year.